Compounds > midazolam

midazolam and atorvastatin

midazolam has been researched along with atorvastatin in 17 studies

Research

Studies (17)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (35.29)	29.6817
2010's	10 (58.82)	24.3611
2020's	1 (5.88)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Andricopulo, AD; Moda, TL; Montanari, CA	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC	1
Bass, JY; Caravella, JA; Chen, L; Creech, KL; Deaton, DN; Madauss, KP; Marr, HB; McFadyen, RB; Miller, AB; Mills, WY; Navas, F; Parks, DJ; Smalley, TL; Spearing, PK; Todd, D; Williams, SP; Wisely, GB	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Dalvie, D; Loi, CM; Smith, DA	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Harte, S; Mc Donnell, CG; O'Driscoll, J; O'Loughlin, C; Shorten, GD; Van Pelt, FD; Van Pelt, FN	1
Mc Donnell, CG; Shorten, G; Van Pelt, FN	1
Grime, K; Riley, RJ; Webborn, PJ	1
Inui, N; Kagawa, Y; Kokudai, M; Sakaeda, T; Takeuchi, K; Watanabe, H	1
Aohara, F; Fujimura, Y; Harakawa, N; Hasegawa, R; Katori, N; Kim, SR; Maekawa, K; Naito, M; Niwa, T; Okuda, H; Sai, K; Saito, Y; Sawada, J; Tohkin, M; Yoshimura, T	1
Azuma, Y; Fujita, T; Haruyama, Y; Ikeda, Y; Kumagai, Y; Maeda, K; Sugiyama, Y; Yamane, N; Yoshida, K	1
Bi, YA; El-Kattan, AF; Fenner, KS; Iseki, K; Kimoto, E; Lai, Y; Linder, C; Walsky, R; Whalen, KM; Xiao, Y; Yang, YS; Zhang, H	1
Liu, L; Liu, X; Tang, X; Wang, S; Xu, J; Yang, T; Zhang, J	1
Cestari, RN; de Oliveira, RDR; de Souza, FFL; Donadi, EA; Lanchote, VL; Nardotto, GHB; Pippa, LF; Rocha, A	1

Reviews

1 review(s) available for midazolam and atorvastatin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

3 trial(s) available for midazolam and atorvastatin

Article	Year
Effects of statins on the pharmacokinetics of midazolam in healthy volunteers. Journal of clinical pharmacology, 2009, Volume: 49, Issue:5 Topics: Adult; Area Under Curve; Atorvastatin; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypnotics and Sedatives; Japan; Male; Midazolam; Pyrroles; Quinolines; Simvastatin	2009
Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clinical pharmacology and therapeutics, 2011, Volume: 90, Issue:4 Topics: Adult; Atorvastatin; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Liver; Male; Metabolic Clearance Rate; Midazolam; Organic Anion Transporters; Pravastatin; Pyrroles; Time Factors; Young Adult	2011
Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. Clinical and translational science, 2020, Volume: 13, Issue:6 Topics: Adolescent; Adult; Area Under Curve; Atorvastatin; Case-Control Studies; Chemokine CCL2; Cytochrome P-450 CYP3A; Female; Healthy Volunteers; Humans; Interleukin-10; Liver-Specific Organic Anion Transporter 1; Lupus Erythematosus, Systemic; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Severity of Illness Index; Signal Transduction; Tumor Necrosis Factor-alpha; Young Adult	2020

Other Studies

13 other study(ies) available for midazolam and atorvastatin

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2007
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24 Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility	2010
Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene. Bioorganic & medicinal chemistry letters, 2011, Feb-15, Volume: 21, Issue:4 Topics: Animals; Binding Sites; Blood Glucose; Crystallography, X-Ray; Diabetes Mellitus, Experimental; Dogs; Fluorescence Resonance Energy Transfer; Humans; Isoxazoles; Ligands; Mice; Molecular Conformation; Naphthalenes; Protein Structure, Tertiary; Quinolines; Rats; Receptors, Cytoplasmic and Nuclear; Weight Gain	2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
Which metabolites circulate? Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5 Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations	2013
The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. Anaesthesia, 2003, Volume: 58, Issue:9 Topics: Aged; Anesthesia, General; Anesthetics, Intravenous; Anticholesteremic Agents; Atorvastatin; Drug Interactions; Female; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matched-Pair Analysis; Midazolam; Middle Aged; Pyrroles	2003
Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro. Anaesthesia, 2005, Volume: 60, Issue:8 Topics: Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypnotics and Sedatives; In Vitro Techniques; Indoles; Microsomes, Liver; Midazolam; Pyrroles	2005
Functional consequences of active hepatic uptake on cytochrome P450 inhibition in rat and human hepatocytes. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:8 Topics: Animals; Atorvastatin; Cells, Cultured; Culture Media; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diclofenac; Enzyme Inhibitors; Estrone; Hepatocytes; Heptanoic Acids; Humans; Hydroxylation; Liver; Midazolam; Pyrroles; Quinolines; Rats; Recombinant Proteins; Tritium	2008
CYP3A416 and CYP3A418 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Alleles; Animals; Asia, Eastern; Atorvastatin; Biocatalysis; Camptothecin; Carbamazepine; Cytochrome P-450 CYP3A; Docetaxel; Heptanoic Acids; Humans; Irinotecan; Midazolam; Models, Molecular; Paclitaxel; Pyrroles; Spodoptera; Substrate Specificity; Taxoids; Terfenadine	2010
Differential modulation of cytochrome P450 activity and the effect of 1-aminobenzotriazole on hepatic transport in sandwich-cultured human hepatocytes. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:2 Topics: Anti-Anxiety Agents; Anticholesteremic Agents; Atorvastatin; Bile; Biological Transport; Cell Survival; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Fluorobenzenes; Hepatocytes; Heptanoic Acids; Humans; Isoenzymes; Midazolam; Models, Biological; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Triazoles	2012
Predicted contributions of cytochrome P450s to drug metabolism in human liver microsomes using relative activity factor were dependent on probes. Xenobiotica; the fate of foreign compounds in biological systems, 2019, Volume: 49, Issue:2 Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Diclofenac; Humans; Kinetics; Microsomes, Liver; Midazolam; Protein Isoforms; Testosterone; Tolbutamide; Verapamil; Warfarin	2019